Argá Medtech PFA Shows 94% Durability in Burst-AF Trial
BURST-AF, a 101-patient first-in-human study of Argá Medtech’s Coherent Sine-Burst Electroporation platform, reported 100% procedural success and 94% overall...
First Youth Enrolled in Promising Pediatric T1D Afrezza Study
MannKind has enrolled the first patient in INHALE-1ST, a U.S. multi-center, single-arm study evaluating Afrezza (inhaled human insulin) initiated...
Innocare IND Approval For New VAV1 Degrader Trial In China
InnoCare Pharma has received CDE approval from China’s NMPA to begin clinical trials of ICP-538, an oral VAV1-directed molecular...
Novo Nordisk Strategic Framework for Fit-for-Purpose Real-World Data
At the 2026 SCOPE Summit, Tom Dougherty, Real World Data Strategy Lead at Novo Nordisk, presented a comprehensive roadmap...
MAPS, Columbia U Partner on First MDMA Couples Therapy Study
Enrollment targets are modest but specific: 50–100 anonymous survey responses and 10–20 confidential interviews, backed by Columbia University IRB...
Halneuron® Phase 2b Trial Reaches 50% Enrollment Milestone
Interim data from Dogwood Therapeutics’ ongoing Phase 2b HALT-CINP study point to a favorable operational and clinical signal: a...
Pulmovant Completes Enrollment for Phase 2 PH-ILD Study
In early clinical testing, a single inhaled dose of mosliciguat reduced pulmonary vascular resistance by up to 38% and...
Onward Study Offers Hope for SCI Blood Pressure Control
Feasibility data published in 2025 reported immediate, sustained increases in blood pressure with implant-based spinal cord stimulation in people...
New Trial Data: Comparable Survival Despite Genetic Mismatch
One-year overall survival exceeded 80% across all mismatch levels in the prospective, 268-patient ACCESS trial of mismatched unrelated donor...
Dewpoint Launches Promising Cancer Trial for Solid Tumors
Dewpoint Therapeutics has dosed the first patient in a Phase 1a/2a study of DPTX3186, a first-in-class small molecule that...